In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Pfizer's current price at $27.46 is below the PERT fair value of $30.33, indicating a moderate implied upside of 10.5%. Valuation methods, particularly DCF and Monte Carlo, show significant upside potential offset by high volatility and a 36.1% downside risk. Fair financial health scores and low growth moderate risk-return balance.